Boundless Bio is a clinical-stage oncology biotech developing small molecule drugs targeting extrachromosomal DNA (ecDNA) — circular DNA fragments found only in cancer cells that allow tumors to rapidly amplify oncogenes and develop resistance to existing therapies. The company's thesis is that conventional precision oncology drugs fail in oncogene-amplified cancers because they target proteins produced by amplified oncogenes rather than the underlying ecDNA biology. Boundless Bio instead targets the cellular machinery that ecDNA depends on to function, aiming to be selectively lethal to cancer cells while sparing healthy tissue. The company has no approved products and no revenue. Its lead candidate, BBI-940, is an oral small molecule degrader of a kinesin protein involved in ecDNA segregation during cell division, currently in a Phase 1 trial (KOMODO-1) in breast cancer patients. Two earlier programs have been discontinued following disappointing clinical results. Boundless Bio funds itself through equity and manages its business around cash runway and clinical milestones. The company's proprietary Spyglass platform — a library of roughly 2,000 cancer cell models with custom ecDNA analytics — is used to identify synthetic lethal targets across the ecDNA lifecycle and could seed future pipeline programs or partnership deals. If BBI-940 gains approval, Boundless Bio intends to commercialize in the U.S. independently or with a partner.